ZNTL
Zentalis Pharmaceuticals, Inc.
10.67
USD
This page is just a preview of the data found in TrendSpider’s full version
Zentalis Pharmaceuticals, Inc. stock is down -34.78% since 30 days ago. The next earnings date is Feb 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 November’s closed higher than October. In the last 3 Unusual Options Trades, there were 2 CALLs, 1 PUT. 75% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 12 Oct 18:48 | 19 Apr, 2024 | 22.50 | 0 | ||
| 20 Oct 18:09 | 17 Nov, 2023 | 22.50 | 49 | ||
| 07 Nov 20:08 | 19 Jan, 2024 | 25.00 | 50 |
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trials. The company has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC, GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd.
